Searched for
URL PHARMA
Sun Pharma: How a small Kolkata trader became a global buyout artistSun Pharma, led by Dilip Shanghvi, is poised for its largest overseas acquisition, a $12.5 billion deal for Organon & Co. This move continu...- Lupin hire Nicholas Hart to head US businessHis past experiences include Business Unit Head for Reproductive Health at Ferring Pharmaceuticals, Inc and Senior Vice President of Sales ...
- Sun Pharma slumps over 6% on USFDA import alert; doxycycline prices fallRanjit Kapadia an analyst at Centrum Broking doesn’t see more than 4-5 per cent revenue hit for the company due to import alert.
- Markets to open on a positive note: Sharekhan’s top-11 picks for OctoberGlobal factors are likely to play on the minds of traders as US shutdown and impending debt deadline are likely to weigh on markets.
- Why Sun Pharma is likely to continue to be an outperformer in pharma sectorSun Pharma is the most valuable pharma stocks as the company is expected to post a strong performance in the quarters ahead.
- Sun Pharma shares gain on strong guidance for doxycyclineSun Pharmaceutical went up 1% after a competitor raised its revenue guidance, citing strong sale of a generic antibiotic also sold by Sun P...
- Sun Pharma in talks to buy Sweden's Meda AB for up to $5 billion: ReportsSun Pharmaceutical Industries is said to be in talks to buy Sweden's pharma firm Meda AB in a deal worth up to $5 billion, according to med...
- CLSA sees over 20% upside in Sun Pharma post Q4 resultsCLSA has maintained ‘buy’ rating on Sun Pharma with a price target of Rs 1220 per share, the Asian focused broker said in a report.
- Sun Pharma is doing great but US Arm Taro may be peakingTaro's Q4 revenue fell sequentially, while local business continued to outperform industry.
- Lupin, Sun Pharma & Cipla top bets within pharma space: Mayuresh Joshi, Angel Broking"Pharma stocks like Lupin, Sun Pharma and Cipla from the large cap space looks extremely good," Mayuresh said.
- Sun Pharma touches record high, taking its m-cap above combined mkt value of DRL, Lupin & CiplaGiven its steep climb, some analysts expect a correction in the stock, which, if it happens, is viewed as a good "buying" opportunity.
- Sun Pharmaceuticals' stock hit a record highThe stock of Sun Pharmaceuticals hit a record high on Tuesday, catapulting its market capitalisation above that of Dr Reddy’s Laboratories,...
- Sun Pharma hits fresh record high, market cap exceeds Rs 1 lakh croreM-cap of Sun Pharma exceeded Rs 1 lakh cr and exceeds total value of DRL, Lupin & Cipla. Sun Pharma is now the 14th most valuable co.
- Pharma companies look to be in better shape in March quarterGrowth in the domestic pharma sector, which has recovered marginally from the December quarter, still remains disappointing.
- Buy Sun Pharma with a target price of Rs 966: KarvyKarvy has maintained its Buy rating, with a price target of Rs 966 on Sun Pharma. The companys’s arm URL Pharma has increased the prices by...
- CLSA upgrades Sun Pharma to 'buy'; raises target price to Rs 990CLSA has upgraded Sun Pharma from 'outperform' to 'buy' rating in a morning note on Wednesday.
- Sun Pharma's US business continues to drive growthDrug maker Sun Pharma's US business continues to drive growth, contributing as it does to over half of the company’s revenues.
- Sun Pharma continues its growth momentum in the December QuarterThe company logged 33% growth in its consolidated net sales and its operating profit margin stood at 44%.
- Pharma sector sees revival of M&AAlong with organic investments, capital deployment by industry is at 7-yr high of around 6% of market capitalization.
- Sun Pharma arm to buy Takeda's US-based generics subsidiary URL PharmaSun Pharmaceutical Industries today said its arm Caraco Pharma will buy Japanese drug maker Takeda Pharmaceuticals' US-based generics subsi...
Load More
